BUY Lupin Limited — Dharmesh Kant, Cholamandalam Securities
byDharmesh Kant, Cholamandalam SecuritiesHorizon: 1 year3 Jul 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Lupin Ltd has received an Establishment Inspection Report (EIR) from the U.S. FDA for its Somerset facility, classifying it with Voluntary Action Indicated (VAI).
BSE · Company Update·1 Jul · yesterday
Lupin Ltd provided updates on the acquisition of minority shareholding in its subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), and a share buyback by MPPI.
BSE · Company Update·1 Jul · yesterday
Lupin announced that the European Medicines Agency (EMA) has approved a change to the marketing authorization for NaMuscla, including new dosage strengths and expanded pediatric indications for non-dy
BSE · Company Update·1 Jul · yesterday
Lupin Limited received tentative approval from the U.S. FDA for Enzalutamide Tablets on June 26, 2026. This is a step towards potential market approval.
NSE · Press Release·26 Jun · 1w ago
4 other SEBI-registered advisors have active long-term BUY calls on this stock
Advisor consensus · same horizon·19 Jun · 2w ago
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.